Aceso Life Science Group Limited (Stock Code: 00474) announced an expected profit of approximately HK$380 million for the six months ended 30 September 2025, in contrast to a loss of around HK$195 million for the same period in 2024. This increase is attributed mainly to a gain on the disposal of a subsidiary during the reporting period.

According to the company's preliminary assessment, the unaudited consolidated management accounts remain subject to review by the external auditor and the audit committee. Final results for the reporting period are anticipated to be released on 28 November 2025. Shareholders and potential investors are urged to exercise caution when trading the company’s securities.